Role of topical immunotherapy in the treatment of alopecia areata. Quality analysis of articles published between January 1977 and January 1988 about three treatments. Reading Group

J Am Acad Dermatol. 1990 Apr;22(4):654-6. doi: 10.1016/0190-9622(90)70092-v.

Abstract

We conducted a survey of clinical trials to assess the scientific evidences presented for the practical use of dinitrochlorobenzene, squaric acid dibutylester, and diphencyprone in the treatment of alopecia areata. Twenty-six papers published between January 1977 and January 1988, in English, French, and Italian were selected. We used a standardized protocol of evaluation, which focused principally on the reporting of methods. Twelve papers were uncontrolled studies. Of the controlled studies, 11 had a self-controlled design, two studies involved the use of parallel concurrent controls, and seven were randomized trials. With regard to criteria for entry, follow-up schedules, and criteria for evaluation of response to treatment, the studies were scored generally poorly; therapeutic regimen, patients' characteristics, withdrawals, and description of side effects in these studies were rated more highly. In light of our results, further and better-designed studies are needed for acceptance of dinitrochlorobenzene, squaric acid dibutylester, and diphencyprone in current therapy.

Publication types

  • Meta-Analysis

MeSH terms

  • Administration, Cutaneous
  • Alopecia Areata / therapy*
  • Cyclobutanes / therapeutic use
  • Cyclopropanes / therapeutic use
  • Dinitrochlorobenzene / therapeutic use
  • Humans
  • Immunotherapy / methods*
  • Meta-Analysis as Topic

Substances

  • Cyclobutanes
  • Cyclopropanes
  • Dinitrochlorobenzene
  • squaric acid dibutyl ester
  • diphenylcyclopropenone